Effect of dexmedetomidine on inflammatory protein signaling pathway in patients with acute lung injury after coronary artery bypass grafting

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045592

Enrollment

Unknown

Registered

2021-04-19

Start date

2021-05-10

Completion date

Unknown

Last updated

2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Intervention Group:Dexmedetomidine pumped continuously

Control Group:Continuous pumping of normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective coronary artery bypass grafting (CABG) had left ventricular ejection fraction (EF) >= 30%, no left atrial thrombus, no myocardial infarction in recent 4 weeks, and no conduction block in ECG; 2. Cardiac function was grade II - IV; 3. All patients had no history of cardiac surgery, no electrolyte or acid-base disturbance; 4. Age was more than 60 years old; 5. All patients or family members voluntarily participated in the experiment and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined infectious diseases; 2. ASA > grade III; 3. Severe heart failure in recent three months; 4. Allergic to dexmedetomidine and other drugs in this study; 5. Allergic to any drug; 6. History of local or systemic hormone therapy; 7. Central nervous system diseases; 8. Severe heart, lung, liver and kidney diseases, metabolic diseases, dehydration etc..

Design outcomes

Primary

Measure	Time frame
receptor for advanced glycation end products,RAGE; high-mobility group box-1, HMGB 1;transforming growth factor-ß1,TGF-ß1;Smad;Nanog;	—

Countries

China

Contacts

Public ContactHu Jie

Luoyang Central Hospital

13721624858@163.com+86 13721624858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026